ASCO 2021| 特瑞普利单抗摘要收录一览

欢迎各位粉丝加入我们！进入公众号主页面，点击下方“加粉丝群”即可扫描入群，或扫描下方二维码入群。

ASCO 2021 已线上公布科研成果接收信息：特瑞普利单抗相关科研成果共获接收27篇。

oral 共 2 篇，含 1 篇 LBA2

ID : LBA2

Type ：Oral

PI ：Ruihua Xu

JUPITER-02: Randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC)

Jupiter-02: 一项特瑞普利单抗或安慰剂联合吉西他滨+顺铂作为一线治疗方案治疗复发或转移性鼻咽癌患者的随机、双盲、III期研究

ID : 9512

Type ：Oral

PI ：Jun Guo

A phase 2 clinical trial of neoadjuvant anti-PD-1 ab (Toripalimab) plus axitinib in resectable mucosal melanoma

一项特瑞普利联合阿昔替尼新辅助治疗可切除黏膜黑色素瘤患者中的Ⅱ期临床研究

Poster 共 10 篇

ID : 2535

Type ：Poster

PI ：Xiubao Ren

A single-arm phase Ib study of multiple target cytotoxic T-lymphocyte (MCTL) in combination with toripalimab as second-line therapy in advanced non-small cell lung cancer (NSCLC)

一项特瑞普利单抗联合多靶向细胞毒性T淋巴细胞治疗(MCTL)二线治疗治疗晚期非小细胞肺癌的单臂Ib期临床研究

ID : 4050

Type ：Poster

PI ：Hongli Li, Jingyu Deng, Shaohua Ge,...Yi Ba

Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma

围手术期特瑞普利单抗联合FLOT方案治疗局部晚期可切除胃/胃食管交界(GEJ)腺癌的II期研究

ID : 4051

Type ：Poster

PI ：Quanli Gao

The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: A phase II study

一项探寻免疫联合化疗新辅助治疗局部晚期食管鳞癌中，应用化疗与抗PD-1单抗用药顺序对疗效影响的II期临床研究 

ID : 4083

Type ：Poster

PI ：MinKe He, Shi Ming, Zhicheng Lai, QiJiong Li

A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study)

仑伐替尼联合特瑞普利单抗，肝动脉灌注化疗治疗晚期肝癌一线的II期研究(LTHAIC研究)

ID : 4094

Type ：Poster

PI ：Zhou Jian, Jia Fan, Guo-Ming Shi

Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial

Gemox化疗联合抗PD-1抗体特瑞普利单抗和仑伐替尼一线治疗晚期肝内胆管癌的II期临床研究

ID : 4099

Type ：Poster

PI ：Zhou Jian, Jia Fan, Guo-Ming Shi

Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial

仑伐替尼联合特瑞普利单抗一线治疗晚期肝内胆管癌的单臂、II期研究

ID : 6023

Type ：Poster

PI ：Mingyuan Chen

Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal  carcinoma : An open-label single-arm, phase II trial

一项特瑞普利单抗联合调强放疗治疗复发鼻咽癌的开放、单臂、II期研究

ID : 6039

Type ：Poster

PI ：Guopei Zhu

Adjuvant toripalimab or combined with S-1 in recurrent, previously irradiated head and neck squamous cell carcinoma treated with salvage surgery: A phase II clinical trial (The RePASS study)

一项特瑞普利单抗单药或联合S-1治疗既往接受过挽救性放疗手术的复发头颈鳞癌患者的II期临床研究 (The RePASS study)

ID : 8541

Type ：Poster

PI ：Long Hao

Phase II trial of toripalimab plus chemotherapy as neoadjuvant treatment in resectable stage III non-small cell lung cancer (NeoTPD01 Study)

一项特瑞普利单抗联合化疗新辅助治疗可切除III期非小细胞肺癌的II期临床研究 (NeoTPD01 Study)

ID : 9573

Type ：Poster

PI ：Jun Guo

Adjuvant anti-PD-1 ab (Toripalimab) versus high-dose IFN-a2b in resected mucosal melanoma: A phase Ⅱ randomized trial

一项特瑞普利单抗对比大剂量干扰素辅助治疗完全切除的黏膜黑色素瘤的随机、对照Ⅱ期临床研究

abstract 共 15 篇

ID : e15500

Type ：abstract

PI ：Weiwei Xiao, Yan Yuan, SuiHai Wang,...Yuanhong Gao

Neoadjuvant PD-1 blockade combined with chemotherapy followed by concurrent immunoradiotherapy for locally advanced anal canal squamous carcinoma patients: Antitumor efficacy, safety and biomarker

PD-1联合化疗后同步免疫放疗新辅助治疗局部晚期肛管鳞癌患者:抗肿瘤疗效、安全性及生物标志物研究

ID : e16015

Type ：abstract

PI ：Xiaolin Lin, Qing Xia, Ting Han, ...Xiuying Xiao

Efficacy and safety of toripalimab combination with SOX regimen as a first-line treatment in patients with unresectable locally advanced or recurrent / metastatic gastric / gastroesophageal junction cancer : Preliminary data from a single-armed, exploratory study

特瑞普利单抗联合SOX方案作为不可切除的局部晚期或复发/转移性胃/食管交界癌的一线治疗的有效性和安全性:来自一项单臂探索性研究的初步数据

ID : e16029

Type ：abstract

PI ：Guochun Cao

Phase-II study of toripalimab combined with neoadjuvant chemotherapy for the treatment of resectable esophageal squamous cell carcinoma

一项特瑞普利单抗联合术前新辅助化疗治疗可切除食管鳞癌的II期临床研究   

ID : e16043

Type ：abstract

PI ：Yonghong Hu

The efficacy and safety of toripalimab combined with definitive chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma

特瑞普利单抗联合根治性同步放化疗治疗局部晚期食管鳞癌的有效性及安全性  

ID : e16094

Type ：abstract

PI ：Qing Wei, Xu Qi, Lei Chen, ...Jieer Ying, Li Jingjing

Sensitive and dynamic CTCs measurement for prediction and monitoring of PD-1 therapy in GC/EGJC patients: Results from a pilot phase 2 study

通过敏感和动态CTCs测量预测和监测PD-1治疗胃癌/胃食管连接部肿瘤的疗效:一项实验性2期研究

ID : e16099

Type ：abstract

PI ：Yang Yang, Jing Yan, Juan Liu, ...Baorui Liu

Phase II study of combining immunotherapy and pulsed low dose rate radiotherapy for abdominal metastasis of gastric cancer

联合免疫治疗和低剂量脉冲放疗治疗胃癌腹部转移的II期研究

ID : e16130

Type ：abstract

PI ：Haifeng Lin

Updated results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma

II期ALTER- H003试验的最新结果:安罗替尼联合特瑞普利单抗治疗不可切除晚期肝癌患者的一线治疗的临床研究

ID : e16170

Type ：abstract

PI ：Wei Li, Yiyi Yu, Xiaojing Xu, ...Tianshu Liu

Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: Update analytic results of an open-label phase II clinical study (JS001-ZS-BC001)

特瑞普利单抗联合化疗作为晚期胆道肿瘤的一线治疗:一项开放，II期临床研究的最新结果(js001-z-BC001)

ID : e16213

Type ：abstract

PI ：Ke Cheng, Wan-Rui Lv, Xiaofen Li, Bole Tian, Dan Cao

Toripalimab with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a single-arm, open-label, phase Ib/II clinical study

特瑞普利单抗联合白蛋白-紫杉醇/吉西他滨一线治疗晚期胰腺腺癌:一项单臂、开放、Ib/II期临床研究

ID : e17016

Type ：abstract

PI ：Hui Han

Immune checkpoint inhibitor plus anti-EGFR target therapy plus chemotherapy in patients with locally advanced penile squamous cell carcinoma

免疫检查点抑制剂联合抗EGFR靶向治疗及化疗治疗局部晚期阴茎鳞癌患者

ID : e20526

Type ：abstract

PI ：Nong Yang

The efficacy and safety of neoadjuvant anti-PD-1 inhibitor combined with platinum-based chemotherapy in patients with potentially resectable non-small cell lung cancer
一项PD1抑制剂联合铂类为基础的化疗新辅助治疗潜在可切除非小细胞肺癌的有效性和安全性研究

ID : e20570

Type ：abstract

PI ：Nan Dai

Efficacy and safety of toripalimab with anlotinib and chemotherapy as first-line therapy in patients with extensive-stage small-cell lung cancer: Preliminary results of an open-label, single-arm, phase II study
特瑞普利单抗联合安罗替尼和化疗作为一线治疗治疗广泛期小细胞肺癌有效性和安全性：一项开放、单臂、II期临床研究初步结果

ID : e21193

Type ：abstract

PI ：Bo Zhu

Real-world outcomes of toripalimab (JS001) in advanced non-small cell lung cancer: A multicenter retrospective study
特瑞普利单抗治疗晚期非小细胞肺癌肺癌的真实世界研究：一项多中心回顾性研究

ID : e21507

Type ：abstract

PI ：Tianwen Gao

The efficacy and safety analysis of PD-1 inhibitor combined with interferon-α1b: A real-world study in Chinese metastatic melanoma patients
一项PD-1抑制剂联合干扰素治疗中国转移性黑色素瘤患者的有效性及安全性的真实世界研究

ID : e21522

Type ：abstract

PI ：Jun Guo

Four-year survival follow-up of toripalimab (JS001) as salvage therapy in Chinese melanoma patients
特瑞普利单抗作为挽救治疗对中国黑色素瘤患者的4年生存随访结果

精彩推荐：

- End -